Palo Alto Investors’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-4,852,383
| Closed | -$413M | – | 45 |
|
|
2020
Q3 | $413M | Sell |
4,852,383
-330,600
| -6% | -$16.7M | 22.65% | 1 |
|
|
2020
Q2 | $184M | Sell |
5,182,983
-107,763
| -2% | -$3.15M | 11.03% | 1 |
|
|
2020
Q1 | $71.3M | Sell |
5,290,746
-632,449
| -11% | -$10.6M | 5.97% | 8 |
|
|
2019
Q4 | $125M | Sell |
5,923,195
-261,125
| -4% | -$4.61M | 6.9% | 5 |
|
|
2019
Q3 | $82M | Sell |
6,184,320
-492,435
| -7% | -$7.24M | 5.46% | 8 |
|
|
2019
Q2 | $92.6M | Buy |
6,676,755
+295,200
| +5% | +$4.44M | 4.5% | 9 |
|
|
2019
Q1 | $123M | Buy |
6,381,555
+1,195,300
| +23% | +$19.3M | 5.11% | 9 |
|
|
2018
Q4 | $74M | Buy |
5,186,255
+172,491
| +3% | +$3.42M | 3.94% | 11 |
|
|
2018
Q3 | $104M | Buy |
5,013,764
+210,400
| +4% | +$4.98M | 4.22% | 9 |
|
|
2018
Q2 | $114M | Buy |
4,803,364
+7,356
| +0.2% | +$148K | 4.54% | 8 |
|
|
2018
Q1 | $70.1M | Buy |
4,796,008
+21,747
| +0.5% | +$355K | 3% | 10 |
|
|
2017
Q4 | $77.2M | Buy |
4,774,261
+1,763,795
| +59% | +$20.8M | 3.32% | 10 |
|
|
2017
Q3 | $42.1M | Hold |
3,010,466
| – | – | 1.77% | 17 |
|
|
2017
Q2 | $26.6M | Buy |
+3,010,466
| New | +$21.1M | 1.24% | 20 |
|
Palo Alto Investors's IMMU Position: Q4 2020 in Review
Palo Alto Investors sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 4,852,383 shares — an estimated $413M sold.
Palo Alto Investors first reported a position in IMMU in Q2 2017 and held it in 14 quarters. The position peaked at $413M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Palo Alto Investors reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Palo Alto Investors sold 4,852,383 Immunomedics Inc shares in Q4 2020, an estimated $413M.
- Palo Alto Investors first reported a position in Immunomedics Inc in Q2 2017 and held it in 14 quarters.
- Palo Alto Investors's Immunomedics Inc position peaked at $413M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Palo Alto Investors's 13F filing for Q4 2020, filed 16 Feb 2021.